Bendamustine induces peripheral lymphodepletion in dogs with relapsed lymphoma
Authors:
- Jennifer A LenzJLJennifer A Lenz
- Laurel UptonLULaurel Upton
- Jonathan MaJMJonathan Ma
- Mia M TaloneMTMia M Talone
- Brandon PengBPBrandon Peng
- Lang JiangLJLang Jiang
- Audrey GhanianAGAudrey Ghanian
- Dillon DidehvarDDDillon Didehvar
- Ester YangEYEster Yang
- Joseph A FraiettaJFJoseph A Fraietta
- Matthew J AthertonMAMatthew J Atherton
Open Access
- 2 November 2026
- journal article
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 40 (6)
Abstract
Background: Chimeric antigen receptor (CAR) T-cell therapy has improved outcomes for many human patients with B-cell lymphoma and provides a rational template for analogous canine patients. To date, the expansion, persistence, and activity of CAR T cells in dogs have been limited. Lymphodepletion supports CAR T-cell engraftment and antitumor activity. In human medical oncology, bendamustine has emerged as a well-tolerated lymphodepleting agent. However, prospective use of bendamustine for dogs with lymphoma has not been characterized. Hypothesis/Objectives: To determine the lymphodepleting activity and tolerability of bendamustine in dogs with relapsed lymphoma. Secondary objectives included monitoring serum cytokines and short-term changes in peripheral tumor burden. Animals: Eleven client-owned dogs with relapsed lymphoma. Methods: Luminescent assays were used to assess the direct cytotoxic activity of bendamustine against canine lymphoid cell lines. A prospective rapid dose-escalation pilot trial was undertaken in 11 dogs with relapsed lymphoma to evaluate tolerability while tracking peripheral lymphocyte counts, serum cytokine concentrations, and lymph node measurements. Results: Bendamustine induced concentration-dependent cytotoxicity in all cell lines tested. Two-dose bendamustine regimens up to 90 mg/m2 were generally well tolerated, with no dose-limiting toxicities observed, and resulted in peripheral lymphodepletion (pretreatment median, 880 cells/μL; posttreatment median, 310 cells/μL), an exploratory decrease in circulating interleukin-6 (pretreatment median, 5.32 pg/mL; posttreatment median, 1.33 pg/mL), and a short-term decrease in peripheral nodal burden in 8 of 11 dogs. Conclusions and clinical importance: Bendamustine was generally well tolerated and induced lymphodepletion in our cohort. These findings support further evaluation of bendamustine as a preconditioning agent before autologous canine CAR T-cell infusion.Keywords
Funding Information
- NIH/National Cancer Institute (NCI) Career Development (K08CA252619)
- National Center for Advancing Translational Sciences of the National Institutes of Health (UL1TR001878)
- Institute for Translational Medicine and Therapeutics of the Perelman School of Medicine and the School of Veterinary Medicine at the University of Pennsylvania
This publication has 31 references indexed in Scilit:
- Immune profiling of canine B cell lymphoma reveals cross-species conservation of prognostic markersScientific Reports, 2025
- Lymphodepletion chemotherapy in chimeric antigen receptor-engineered T (CAR-T) cell therapy in lymphomaBone Marrow Transplantation, 2025
- Bendamustine lymphodepletion is a well‐tolerated alternative to fludarabine and cyclophosphamide lymphodepletion for axicabtagene ciloleucel therapy for aggressive B‐cell lymphomaAmerican Journal of Hematology, 2023
- CAR immune cells: design principles, resistance and the next generationNature, 2023
- Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell lymphomasAnnals of Oncology, 2022
- Establishing a model system for evaluating CAR T cell therapy using dogs with spontaneous diffuse large B cell lymphomaOncoImmunology, 2019
- An introduction to chimeric antigen receptor (CAR) T‐cell immunotherapy for human cancerAmerican Journal of Hematology, 2019
- Adoptive cellular therapies: the current landscapeVirchows Archiv, 2018
- Canine lymphoma: a reviewVeterinary Quarterly, 2016
- Simultaneous elevation of the serum concentrations of vascular endothelial growth factor and interleukin‐6 as independent predictors of prognosis in aggressive non‐Hodgkin's lymphomaEuropean Journal of Haematology, 2002